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The accumulation of b-amyloid in the brain is an early event in Alzheimer’s disease. This study presents the ﬁrst patient with
Alzheimer’s disease who underwent positron emission tomography imaging with the amyloid tracer, Pittsburgh Compound B to
visualize ﬁbrillar b-amyloid in the brain. Here we relate the clinical progression, amyloid and functional brain positron emission
tomography imaging with molecular neuropathological alterations at autopsy to gain new insight into the relationship between
b-amyloid accumulation, inﬂammatory processes and the cholinergic neurotransmitter system in Alzheimer’s disease brain. The
patient underwent positron emission tomography studies with
18F-ﬂuorodeoxyglucose three times (at ages 53, 56 and 58 years)
and twice with Pittsburgh Compound B (at ages 56 and 58 years), prior to death at 61 years of age. The patient showed a
pronounced decline in cerebral glucose metabolism and cognition during disease progression, while Pittsburgh Compound B
retention remained high and stable at follow-up. Neuropathological examination of the brain at autopsy conﬁrmed the clinical
diagnosis of pure Alzheimer’s disease. A comprehensive neuropathological investigation was performed in nine brain regions to
measure the regional distribution of b-amyloid, neuroﬁbrillary tangles and the levels of binding of
3H-nicotine and
125I-a-bungarotoxin to neuronal nicotinic acetylcholine receptor subtypes,
3H-L-deprenyl to activated astrocytes and
3H-PK11195 to microglia, as well as butyrylcholinesterase activity. Regional in vivo
11C-Pittsburgh Compound B-positron
emission tomography retention positively correlated with
3H-Pittsburgh Compound B binding, total insoluble b-amyloid, and
b-amyloid plaque distribution, but not with the number of neuroﬁbrillary tangles measured at autopsy. There was a negative
correlation between regional ﬁbrillar b-amyloid and levels of
3H-nicotine binding. In addition, a positive correlation was found
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11C-Pittsburgh Compound B positron emission tomography retention and
3H-Pittsburgh Compound B binding
with the number of glial ﬁbrillary acidic protein immunoreactive cells, but not with
3H-L-deprenyl and
3H-PK-11195 binding. In
summary, high
11C-Pittsburgh Compound B positron emission tomography retention signiﬁcantly correlates with both ﬁbrillar
b-amyloid and losses of neuronal nicotinic acetylcholine receptor subtypes at autopsy, suggesting a closer involvement of
b-amyloid pathology with neuronal nicotinic acetylcholine receptor subtypes than with inﬂammatory processes.
Keywords: Alzheimer’s disease; autopsy brain;
11C-PIB positron emission tomography; inﬂammation; nicotinic acetylcholine receptors
Abbreviations: Ab = b-amyloid;
3H-PIB =
3H-Pittsburgh Compound B;
11C-PIB =
11C-Pittsburgh Compound B;
18F-FDG =
18F-Fluorodeoxyglucose; PET = Positron emission tomography
Introduction
The underlying pathology of Alzheimer’s disease is believed to
precede the onset of clinical symptoms by many years (Thal
et al., 2002). It has been hypothesized that the formation and
accumulation of b-amyloid (Ab) in the Alzheimer’s disease brain
triggers a cascade of neurodegenerative events, including inﬂam-
matory processes, oxidative stress, neuroﬁbrillary tangles, neuronal
network dysfunction with synaptic loss and neurotransmitter def-
icits (Braak and Braak, 1991; Nordberg, 2001; Thal et al., 2002;
Ingelsson et al., 2004; Mattson, 2004; Price et al., 2009), which
are manifested clinically by progressive impairment of cognitive
functions. Previously, a deﬁnite diagnosis of Alzheimer’s disease
was considered only possible by post-mortem histopathological
analysis of the brain; however, the development of new biomark-
ers including the amyloid positron emission tomography (PET)
tracer Pittsburgh Compound B (
11C-PIB) for visualizing ﬁbrillar
Ab, has created new possibilities for early detection of brain
impairments.
Several
11C-PIB PET studies in different cohorts of patients have
shown a consistent high load of ﬁbrillar Ab in large parts of the
Alzheimer’s disease brain compared to healthy controls and other
forms of dementia (Nordberg et al., 2010). Longitudinal amyloid
imaging studies in subjects with mild cognitive impairment and
Alzheimer’s disease have suggested that the ﬁbrillar Ab levels in
the brain reach a plateau early on and remain stable during the
disease progression, whereas neurodegeneration and clinical
decline measured by
18F-ﬂuorodeoxyglucose (
18F-FDG), MRI and
cognitive tests accelerate and proceed independently of amyloid
accumulation (Engler et al., 2006; Forsberg et al., 2008, 2010;
Jack et al., 2009; Scheinin et al., 2009; Furst et al., 2010; Kadir
et al., 2010). It has also been shown that the retention of
11C-PIB
in vivo correlates well with autopsy measures of Ab deposition in
the Alzheimer’s disease brain, but not with tau (Ikonomovic et al.,
2008).
We aimed to understand the relationship between clinical and
pathological interactive mechanisms by investigating ﬁbrillar Ab
accumulation, inﬂammatory processes and the cholinergic neuro-
transmitter system in an Alzheimer’s disease brain, because these
may be validated as PET biomarkers to reﬂect early changes as
well as disease progression.
A 56-year-old female patient with Alzheimer’s disease volun-
teered in February 2002 for the ﬁrst
11C-PIB PET scan in the
world (Klunk et al., 2004). The patient died in August 2007, 35
months after having participated in a second
11C-PIB PET scan,
in August 2004. The results from the clinical longitudinal cog-
nitive assessments as well as the repeated
11C-PIB and
18F-FDG
PET imaging scans were assessed in relation to the autopsy data
for Ab plaques and neuroﬁbrillary tangle distribution, as well as
other pathological markers known to affect brain network func-
tion, including markers of inﬂammation (activated microglia and
astrocytes) and neuronal nicotinic acetylcholine receptor losses in
different brain regions.
Case history and methods
Clinical description
In 1999, a female patient aged 53 years, was referred from a local
hospital to the Department of Geriatric Medicine at Karolinska
University Hospital Huddinge, Stockholm, Sweden. The patient
had no known family history of dementia or other neurodegen-
erative diseases. In addition to the patient’s own experience of
cognitive problems a couple of years prior, during her occupation
as a nurse, relatives conﬁrmed difﬁculties with memory, both at
work and at home. The patient underwent a thorough clinical
investigation including medical history, cognitive screening, phys-
ical and neurological examinations as well as laboratory blood
tests, including apolipoprotein E genotyping, neuropsychological
assessment, lumbar puncture, electroencephalography (EEG), com-
puted tomography (CT) and single photon emission computed
tomography imaging (SPECT). The CT scan was normal; however,
the SPECT scan showed decreased cerebral perfusion bilateral in
the parietal cortex, predominantly on the left side. EEG inves-
tigation showed decreased alpha amplitude as well as theta/delta
activity. Analysis of cerebrospinal ﬂuid (CSF) biomarkers revealed
pathological values with Ab42 438pmol/ml (5450pmol/ml is
abnormal) and tau 1180pmol/ml (4400pmol/ml is abnormal).
The patient was an ApoE e 4/4 carrier. The clinical diagnosis of
Alzheimer’s disease was made in accordance with the criteria from
the workgroup formed by the National Institute of Neurological
and Communication Disorders and Stroke-Alzheimer’s disease and
Related Disorders Association (NINCDS-ADRDA) (McKhann et al.,
1984). The patient received treatment with the cholinesterase in-
hibitor rivastigmine (12mg daily) and at a more advanced stage of
the disease, she was also treated with memantine (20mg daily).
The patient was clinically assessed (by A.N.), every 6 months from
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was admitted to a nursing home, 4 months prior to her death at
61 years of age. Consent from next of kin was given for research
studies prior to autopsy.
Neuropsychological assessments
An experienced neuropsychologist (O.A.) performed cognitive as-
sessments at regular intervals during 1999–2006. These neuropsy-
chological tests included a global scale test, i.e. the full-scale
intelligence quotient (FSIQ) test, as well as cognitive tests used
to assess speciﬁc domains such as verbal abilities (similarities and
information), visuospatial abilities (block design and Rey–
Osterrieth copying), short-term memory (digit span and corsi
span), episodic memory (Rey auditory verbal learning and reten-
tion after 30min; Rey-Osterrieth Retention after 30min) and at-
tention and executive function (Digit Symbol and Trail Making
Test A and B). Detailed information regarding the above-
mentioned tests has been described previously (Almkvist and
Tallberg, 2009). In order to make comparisons between various
neuropsychological test results, all cognitive raw scores were z-
transformed by using reference data from healthy adults at the
Geriatric Clinic, Karolinska University Hospital Huddinge (Bergman
et al., 2007).
Magnetic resonance imaging
MRI was performed at the age of 53 using a 1.5 T scanner
(Magnetom Vision Plus, Siemens, Germany) and included a
T1-weighted 3D magnetization-prepared rapid gradient echo se-
quence (MP-RAGE), repetition time: 11.4ms, effective echo time:
4.4ms, ﬂip angle: 10, slice thickness: 2.5mm.
Medial temporal lobe atrophy was assessed visually according to
the Scheltens scale (Scheltens et al., 1992) on coronal 3D
magnetization-prepared rapid gradient echo sequence slices per-
pendicular to the anterior commissure and the posterior commis-
sure line at the mid-level of the brainstem after having amygdala
in front.
The medial temporal lobe atrophy scale ranges from 0 (no at-
rophy) to 4 (severe atrophy) and takes into account the width of
the choroidal ﬁssure, the height of the hippocampus and the width
of the temporal horn of the lateral ventricle. Left and right medial
lobe atrophy was rated separately. A trained rater, who was
blinded to the clinical information of this case, rated the medial
temporal lobe atrophy.
Positron emission tomography
The PET examinations with
18F-FDG and
11C-PIB were performed
at Uppsala Academic Hospital, Sweden. Production of
18F-FDG
and
11C-PIB was carried out according to standard manufacturing
processes and synthesis of
11C-PIB was performed by means of a
previously described method (Mathis et al., 2003; Klunk et al.,
2004).
Positron emission tomography
scanning:
18F-ﬂuorodeoxyglucose
From 1999 to 2004, the patient underwent three
18F-FDG PET
scans at ages 53, 56 and 58 years. The PET scans were performed
using Siemens ECAT EXACT HR+ scanners (CTI PET-Systems,
Inc., Knoxville TN, USA) with an axial ﬁeld of view of 155mm,
providing 63 contiguous 2.46mm slices with 5.6mm transaxial
and 5.4mm axial resolution. The patient was scanned under rest-
ing condition after fasting for 4h. The orbito-meatal line was used
to centre the heads of the subject. The data were acquired in a 3D
mode. The administered mean
18F-FDG tracer dose was 210 MBq.
The scanner protocol for transmission, emission and reconstruction
has been described previously (Klunk et al., 2004; Engler et al.,
2006).
Parametric maps of regional cerebral glucose metabolism were
generated by means of the Patlak method using the time course
of the tracer in the arterialized venous plasma samples as an input
function (Patlak et al., 1983). The frames from 20 to 60min and a
lumped constant of 0.418 were used to generate the parametric
maps of regional cerebral glucose metabolism. All values are ex-
pressed in mmol/min/100 g.
Positron emission tomography
scanning:
11C-Pittsburgh Compound B
In February 2002, the patient underwent the ﬁrst
11C-PIB PET
scan at 56 years of age, with an additional
11C-PIB PET scan
performed in August 2004, at 58 years of age. The protocols
for the
11C-PIB PET examinations, including the scanner protocol
for transmission, emissions and reconstructions are described in
detail in the above-mentioned studies (Klunk et al., 2004;
Engler et al., 2006). The
11C-PIB examinations were performed
using a Siemens ECAT EXACT HR+ scanner (CTI PET-systems
Inc.), with an axial ﬁeld of view of 155mm, providing 63
contiguous 2.46mm slices with a 5.6mm transaxial and a
5.4mm axial resolution. The mean tracer dose of
11C-PIB was
320 MBq.
The
11C-PIB retention data were calculated as standard uptake
values as previously described in detail (Klunk et al., 2004) and
were obtained in a late time interval (40–60min).
Regions of interest
A set of standardized regions of interest was used to determine
the inter-relation between PET data and cognitive tests and to
compare the PIB scans 1 and 2. The region of interest placement
procedure has been described in detail (Scho ¨ll et al., 2009). A
computerized reorientation procedure developed in-house was
used to align consecutive
18F-FDG- and
11C-PIB-PET images for
accurate intra-comparison and application of regions of interest
(Andersson and Thurfjell, 1997). The
18F-FDG images were
realigned to the ﬁrst
18F-FDG image and the
11C-PIB images at
baseline and follow-up were co-realigned using the respective
18F-FDG images as templates. To compare the baseline and
follow-up
11C-PIB scans, the regional
11C-PIB retention values
were normalized to the corresponding uptake in a cerebellar
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ence region because of its previously reported lack of Congo red-
and thioﬂavin-S-positive plaques (Yamaguchi et al., 1989; Mirra
et al., 1994).
Statistical parametric mapping methods
Voxel based analysis with statistical parametric mapping (SPM5)
(Wellcome Department of Cognitive Neurology, Institute of
Neurology, London, UK), which was implemented using Matlab
7.1 (MathWorks Inc., Sherborn, MA), was used to compare the
regional cerebral glucose metabolism at the age of 53, 56 and 58
with a healthy control population [n = 6, mean age 67.3  8.8
standard deviation (SD)]. All reconstructed PET images were spa-
tially normalized into the Montreal Neurological Institute standard
template (McGill University, Montreal, Canada) to remove
inter-scan and inter-subject anatomical variability. Spatially nor-
malized images were smoothed by convolution, using an isotropic
Gaussian kernel with 8mm full-width at half-maximum.
Proportional scaling was used for global normalization.
Voxel-wise two-sample t-test for comparison between-group
(patient with Alzheimer’s disease versus healthy controls) was
computed at the three time points, with P-values uncorrected
for multiple comparisons. The brain areas that showed glucose
hypometabolism at a peak threshold of P = 0.001 (uncorrected)
and an extent threshold of 50 voxels were investigated. For visu-
alization of the t-score statistics (statistical parametric mapping t-
map), the signiﬁcant voxels were projected onto the 3D rendered
brain thus allowing anatomical identiﬁcation. The Montreal
Neurological Institute coordinates of the local maximum of each
cluster were converted into Talairach coordinates (Talairach and
Tournoux, 1988).
Neuropathology and
immunohistochemistry
The brain was obtained with a post-mortem delay of 17h. At
autopsy, small samples from nine regions of interest: the frontal,
temporal, parietal and occipital cortices, the anterior and posterior
part of the hippocampus, striatum, thalamus and the cerebellum
were collected from the left hemisphere and frozen at 70C.
Coronal sections of the left hemisphere were frozen separately.
The right half of the brain was ﬁxed in 4% formaldehyde.
Material for histopathological examination was collected according
to the Brain Net Europe guidelines (Alafuzoff et al., 2006) after 3
weeks of ﬁxation. Staining for pathological evaluation was per-
formed on 5mm thick formaldehyde ﬁxed parafﬁn-embedded
sections. Sections were routinely stained with haematoxylin and
eosin, luxol fast blue, Bielschowsky silver stain and Congo red. The
diagnostic evaluation was performed by an experienced clinical
neuropathologist (I.N.).
For further characterization of the pathological lesions and for
correlation with the PIB analysis, immunohistochemistry was per-
formed on sections mounted on SuperFrost Slides (Thermo
Scientiﬁc, Waltham, MA, USA). Pretreatment with formic acid
(88%) for 10min was carried out in connection with incubation
with b-amyloid antibodies. Staining was performed using antibo-
dies diluted in Bond
TM primary antibody diluent (Vision BioSystems
Limited, Newcastle upon Tyne, UK), speciﬁc for Ab40 and Ab42
(BioSource, USA), Ab clone 6F/3D (DakoCytomation, Denmark),
Ab 6E10, Ab 4G8 (Chemicon International, Temecula, USA), glial
ﬁbrillary acidic protein (DakoCytomation, Denmark) and tau AT8
(Innogenetics, Belgium). A summary of the primary antibodies
used is shown in Supplementary Table 1. Negative controls con-
sisted of sections incubated in the absence of a primary antibody.
All sections were counterstained with haematoxylin.
The semiquantitative analysis was assessed by the frequency of
senile plaques, neuroﬁbrillary tangles and astrocytes in areas of
maximum density as described previously (Mirra et al., 1991;
Cummings et al., 1996). The densities were expressed as the ab-
sence of immunoreactivity (), rare number of proﬁles (+),
sparse number of proﬁles (+ +), moderate number of proﬁles
(+ + +), frequent proﬁles (++++)a n dextensive or widespread
proﬁles (+++++) (Table 1). In each of the nine regions of
interest, the number of senile plaques, neuroﬁbrillary tangles and
astrocytes was counted and the total number was averaged from
each region of study. All sections were imaged sequentially under
light microscopy and counted in 200 magniﬁcation during a
Table 1 Semi-quantitative immunohistochemical assessments of Ab plaques, neuroﬁbrillary tangles and reactive astrocytes
in autopsy brain of the patient with Alzheimer’s disease
Regions Ab (1–40) Ab (1–42) Ab (6F/3D) Ab (4G8) (EC) Ab (4G8) (IC) Ab (6E10) NFTs (tau AT8) Astrocytes (GFAP)
Count Score Count Score Count Score Count Score Count Score Count Score Count Score Count Score
Frontal 20 + + 61 + + + + 69 + + + + 61 + + + + 61 + + + 26 + + 13 + 74 + + + + +
Temporal 8 + 41 + + + 57 + + + 53 + + + 65 + + + 9 + 29 + + + 62 + + + + +
Parietal 20 + + 92 + + + + + 99 + + + + + 70 + + + + 43 + + + 19 + 3 + 62 + + + + +
Occipital 29 + + 44 + + + 54 + + + 66 + + + + 54 + + + 23 + + 3 + 51 + + + +
H i p p oA 7 + 1 3 + 1 2 + 2 0 ++ 1 0 6 ++++ 5 + 6 9 +++++ 3 9 +++
Hippo P 7 + 9 + 14 + 14 + 158 + + + + + 4 + 50 + + + + 39 + + +
Putamen 3 + 34 + + 14 + 23 + + 106 + + + + 0  4+ 3 1 + + +
Thalamus 3 + 9 + 5 + 14 + 35 + + 4 + 14 + + 38 + + +
Cerebellum 0  1 +1 2 +1 7 + 2 6 +0  0  2+
EC = extracellular; GFAP = glial ﬁbrillary acidic protein; Hippo A = hippocampus anterior; Hippo P = hippocampus posterior; IC = intracellular.
Score: () absent, (+) rare, (+ +) sparse, (+ + +) moderate, (+ + + +) frequent, (+ + + + +) extensive.
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Measurement of b-amyloid levels
Soluble and insoluble Ab40 and Ab42 were quantiﬁed in brain
homogenates of frozen tissue (150–200mg) using commercial
enzyme-linked immunosorbent assay kits (Signal Select
TM Human
b-amyloid 1–40 and 1–42 from BioSource International
Inc., Camarillo, CA, USA) according to a previous protocol
(Hellstrom-Lindahl et al., 2004). Levels of Ab were expressed as
pg/mg tissue.
Neurochemical binding and enzyme
assays
Fresh-frozen autopsy tissue samples (grey matter) from the nine
regions of interest were homogenized in cold 0.32 M sucrose con-
taining protease inhibitors. The homogenates were aliquoted and
frozen at 80C until the binding assays were carried out.
Saturation binding with
3H-Pittsburgh Compound B (
3H-PIB)
was performed in homogenate tissue from the frontal cortex
(100mg tissue) by incubation with 0.2 to 300nM
3H-PIB (speciﬁc
activity 68Ci/mmol, custom synthesis, GE Healthcare, Germany).
Non-speciﬁc binding was determined in the presence of 1mM
unlabelled PIB (Sigma-Aldrich). Saturation binding analysis re-
vealed high-afﬁnity binding for
3H-PIB (Kd = 3.5nM) and 1nM
3H-PIB was used in all subsequent measurements of high-afﬁnity
binding sites.
3H-nicotine and
125I-a-bungarotoxin binding to the two major
neuronal nicotinic acetylcholine receptor subtypes in the brain
(a4b2 and a7) as well as
3H-PK11195 and
3H-L-deprenyl binding
to activated microglia cells and monoamine oxidase B present in
activated astrocytes, was measured by incubating homogenates
from the nine brain regions with
3H-nicotine (5.0nM, speciﬁc ac-
tivity 75Ci/mmol, NEN Life Science Products) (Marutle et al.,
1998),
125I-a-bungarotoxin (2nM, speciﬁc activity 108.8Ci/
mmol, Perkin Elmer, Waltham, MA, USA) (Guan et al., 2001),
3H-PK11195 (5.0nM, speciﬁc activity 83.4Ci/mmol, American
Radiolabeled Chemicals, St Louis, MO, USA) (Kumlien et al.,
1992) and
3H-L-deprenyl (10nM, speciﬁc activity 80Ci/mmol,
Larodan Fine Chemicals AB, Malmo ¨, Sweden) (Jossan et al.,
1991a). Speciﬁc binding values were expressed as fmol/mg
tissue or fmol/mg protein. Butyrylcholinesterase activity was mea-
sured by using a modiﬁed Ellman’s colorimetric assay as described
by Darreh-Shori et al. (2006).
Analysis of in vivo and in vitro
correlations
To match the regional autopsy values from the nine different re-
gions of interest with the corresponding regional
11C-PIB PET re-
tention and
18F-FDG PET uptake values, the corresponding regions
of interest were ﬁrst drawn in accordance with the Brain Net
Europe guidelines (Alafuzoff et al., 2006) on the same MRI cor-
onal levels with the necessary adjustments for exclusion of white
matter. Thereafter, the regions of interest were copied onto the
coregistered
11C-PIB and
18F-FDG-PET scans. Supplementary
Figure 1 illustrates the placement of regions of interest on coronal
hemispheres and how these regions of interest were used in the
correlation analyses. Data from the last
11C-PIB (standard uptake
value) and
18F-FDG PET (mmol/min/100g), 35 months prior to
death, were used in correlations with data obtained from
measurements performed in the autopsy brain tissue.
Statistical analysis
In sum, 43 correlations were performed across this entire study
(
11C-PIB versus 12 parameters;
3H-PIB versus 10 parameters;
18F-FDG versus six parameters; and
3H-L-deprenyl versus two
parameters; glial ﬁbrillary acidic protein immunoreactive cells
versus seven parameters;
3H-nicotine versus three parameters;
125I-a-bungarotoxin versus three parameters). Correlation analyses
were performed by using non-parametric Spearman’s rank order
correlation. Due to the explorative nature of the study and the low
statistical power (as nine brain regions were used in the correl-
ations), statistical Bonferroni correction for multiple comparisons
yielding a signiﬁcant level 0.0012 (0.05/43) was not carried out.
The level of statistical signiﬁcance was set at 0.05 (two-sided). This
implies that the results should be interpreted with some caution.
In addition, stepwise regression analysis was performed to
determine correlations between cognitive test performances
and regional cerebral glucose metabolism as measured by
18F-FDG PET in various brain areas during the progression of dis-
ease (age 53–58 years).
Results
Longitudinal study of cognition,
18F-ﬂuorodeoxyglucose uptake and
11C-Pittsburgh Compound B retention
by positron emission tomography
The ﬁrst neuropsychological assessment of the patient with
Alzheimer’s disease, at 53 years of age, revealed signiﬁcant cog-
nitive impairment, particularly in visuospatial ability, short-term
memory and executive functioning, while verbal ability was pre-
served (Fig. 1A). The mini-mental state examination score was
27 out of 30 during the ﬁrst visit to the Geriatric Clinic at age
53, and progressively declined over the course of the disease with
a score of 5 out of 30 during the last cognitive assessment at the
age of 60 years. The pattern of decline in mini-mental state exam-
ination scores was best-ﬁt to a curvilinear regression line (r = 0.97,
Fig. 1B). Progressive decline was longitudinally observed in other
cognitive tests such as global cognition, episodic memory and at-
tention (Fig. 1C).
The MRI scan was performed as part of the clinical assessment
at 53 years of age. No infarction or haemorrhage was noted. The
patient had discrete bilateral parietal atrophy (Fig. 2A and B), and
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1 (left side) and 1–2 (right side) (Fig. 2C).
Voxel-based analysis of
18F-FDG-PET using statistical parametric
mapping was performed to visualize the decline in regional cere-
bral glucose metabolism in the patient, compared with that from a
group of healthy control subjects. The 3D-rendered image of the
voxel mapping showed signiﬁcant decreases in regional cerebral
glucose metabolism in certain brain regions (right hemisphere:
superior parietal lobule, inferior parietal lobule, precuneus, superior
frontal gyrus, inferior frontal gyrus, superior temporal gyrus, para-
hippocampal gyrus and fusiform gyrus; left hemisphere: inferior
parietal lobule, superior frontal gyrus; all P = 0.001 uncorrected,
k = 50) at the ﬁrst
18F-FDG-PET scan at 53 years of age (Fig. 3A).
In line with the cognitive decline, there was also a pronounced
decrease in regional cerebral glucose metabolism with disease
progression as illustrated with voxel-based statistical parametric
mapping analysis at 56 and 58 years of age, compared with the
healthy control group (Fig. 3B and C).
By using the stepwise regression analysis, we observed that re-
gional cerebral glucose metabolism, in three areas of the brain that
are affected early on in the disease course (medial temporal, pos-
terior cingulate and lower parietal), signiﬁcantly correlated
(P50.05) with test scores for attention, episodic memory and
FSIQ during progression of the disease (Fig. 4).
The ﬁrst
11C-PIB scan at 56 years of age (mini-mental state
examination 21/30) showed high
11C-PIB retention especially in
the frontal, parietal, parietotemporal, temporal, posterior cingulate
and in the striatum (Fig. 5A and B). At 2 year follow-up
(mini-mental state examination 13/30), the cortical
11C-PIB reten-
tion remained high and relatively unchanged (Fig. 5A and B), in
contrast to the continuous decline observed in regional cerebral
glucose metabolism paralleling the decline in cognitive perform-
ance (Figs 1 and 3).
Semi-quantitative immunohistochem-
ical assessment of neuropathology
at autopsy
The brain weighed 1100g. Macroscopic inspection showed a
widening of sulci and cortical and hippocampal atrophy. The an-
terior part of the hippocampus had a particularly reduced size and
the ventricles were slightly enlarged. The histopathological exam-
ination revealed a pure Alzheimer’s disease pathology (Braak stage
6, deﬁnite CERAD) conﬁrming the clinical diagnosis of Alzheimer’s
disease. Congo red staining showed several positive vessels in the
leptomeninges and the cortex, consistent with cerebral amyloid
angiopathy.
Immunohistochemical assessment of the regional distribution of
different types of Ab-containing plaques showed varied staining
patterns with Ab antibodies with different epitope speciﬁcity.
More plaques were stained with antibodies for Ab1–42, 4G8 (re-
active to amino acid residue 17–24) and 6F/3D (residue 8–17)
when compared with antibodies for Ab1–40 and 6E10 (residue
1–17) (Fig. 6A–E). 4G8 labelled both plaques and intracellular
Ab deposits in all the regions studied. A high distribution of intra-
cellular Ab was detected by 4G8 in the hippocampus (score
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Figure 1 (A) Neuropsychological test performances presented
as z-transformed raw scores in the patient with Alzheimer’s
disease at the age of 53 years. (B) Curvilinear regression
(r = 0.97) between age (from 53 to 60 years) and mini-mental
state examination (MMSE) score. (C) Longitudinal data on three
cognitive subtests presented as z-transformed raw scores.
Closed circles = episodic memory; open squares = digit symbol
attention test; ﬁlled squares = full-scale intelligence quotient test
(FSIQ); BD = block design; Cosp = corsi span; Disp = digit span;
Disy = digit symbol; Inf = information; RAVlear = Rey auditory
verbal learning; RAVret = Rey auditory verbal retention;
ROc = Rey–Osterrieth copying; ROret = Rey–Osterrieth reten-
tion; Sim = similarities; TMT A and B = trail making A and B.
306 | Brain 2011: 134; 301–317 A. Kadir et al.Figure 3 Upper row illustrates the positron emission tomography images of the regional cerebral glucose metabolism (mmol/min/100g)
as measured by
18F-ﬂuorodeoxyglucose (
18F-FDG). The coregistered transaxial images are presented at the level of the thalamus at the
age of 53 (A), 56 (B) and 58 (C) years. The red colour indicates high, yellow medium and blue low
18F-FDG tracer uptake. Lower row
illustrates the 3D brain-rendering representation of statistical parameter mapping of
18F-FDG-PET images. Areas of red depict areas in
which the regional cerebral glucose metabolism was signiﬁcantly decreased in the patient with Alzheimer’s disease at the age of 53, 56 and
58 years compared with a group of healthy control subjects (P = 0.001, uncorrected, k = 50). MMSE = mini-mental state examination.
Figure 2 T1-weighted MRI scan at the transaxial (A) and coronal (B) sections showing the bilateral parietal atrophy. MRI scan at the
coronal section showing the medial temporal lobe atrophy score for the hippocampus (C). MMSE = mini-mental state examination.
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cortical plaques were detected in the parietal cortex (score
+++++ with Ab1–42 and 6F/3D and score ++++ with
4G8), and the frontal cortex (score ++++ with all three anti-
bodies), consistent with the neuropathological diagnosis (Table 1).
In contrast, a diffuse distribution of senile plaques was observed in
the hippocampus, striatum, thalamus and cerebellum (ranging in
score from + + to  with all antibodies). Neuroﬁbrillary tangles
were prominent in the anterior hippocampus (score +++++,
Fig. 6G and H) and scattered in the frontal, parietal and the oc-
cipital lobe cortices. In the hippocampus, an overlap between
areas with high tau AT8 immunoreactivity and intracellular 4G8
staining was observed (Table 1). Glial ﬁbrillary acidic protein
immunoreactivity was higher in cortical regions in comparison to
non-cortical regions and reactive astrocytes were observed in areas
with large amounts of amyloid plaque clusters (Fig. 6F). Many of
the vessels in the leptomeninges and cortex were stained with the
amyloid antibodies. There was a variation in the number of stained
vessels with the antibodies used, most abundant with Ab1–40.
Regional
11C-Pittsburgh Compound B
positron emission tomography retention
and b-amyloid levels at autopsy
The regional
11C-PIB retention measured by PET, at both 56 and
58 years of age, showed a positive correlation with the regional
3H-PIB binding (P 5 0.001) as well as the total insoluble Ab levels
(P 5 0.01) measured in autopsy brain tissue (Fig. 7A and B). A
high ﬁbrillar amyloid load visualized with
11C-PIB PET in the front-
al and parietal cortex corresponded with the highest measured
3H-PIB binding as well as the highest levels of total insoluble Ab
in these same regions at autopsy.
Across nine brain regions, in vivo
11C-PIB retention showed
signiﬁcant positive correlations with semi-quantitative neuropatho-
logical assessment of Ab antibody 6F/3D (P50.001), Ab 1–42
(P50.02) and extracellular Ab 4G8 (P50.02) immunoreactivity
(Supplementary Fig. 2A–C). Similarly, signiﬁcant positive correl-
ations were also observed in in vitro
3H-PIB binding and 6F/3D
(P50.02), Ab 1–42 (P50.008) and extracellular Ab 4G8
(P50.05) immunoreactive plaques (Supplementary Fig. 2D–F).
No signiﬁcant correlation was observed between in vivo
11C-PIB
retention or
3H-PIB binding and intracellular 4G8-stained Ab.
11C-Pittsburgh Compound B,
18F-ﬂuorodeoxyglucose positron
emission tomography and regional
distribution of neuroﬁbrillary tangles
at autopsy
There was no correlation between regional distribution of in vivo
11C-PIB retention or
3H-PIB binding and AT8 tau immunopositive
staining for neuroﬁbrillary tangles in autopsy brain (data not
shown). A weak non-signiﬁcant negative correlation (P50.07)
was observed between in vivo regional cerebral glucose metabol-
ism as measured by
18F-FDG PET and neuroﬁbrillary tangles
(Supplementary Fig. 3), which was driven by the anterior and
posterior hippocampus, reﬂecting the predominance of neuroﬁb-
rillary tangles in these regions.
11C-Pittsburgh Compound B positron
emission tomography retention,
3H-Pittsburgh Compound B and
3H-nicotine binding at autopsy
Figure 8A illustrates the low number of
3H-nicotine binding sites
(a4b2 neuronal nicotinic acetylcholine receptors) especially in cor-
tical regions (frontal, parietal and temporal) of the Alzheimer’s
disease brain in comparison with the regional
3H-nicotine binding
in an age-matched control group (historical data from our research
laboratory). A weak negative correlation was observed between
regional in vivo
11C-PIB retention and
3H-nicotine binding at aut-
opsy (P50.06, Fig. 8B), while a stronger negative correlation was
observed between
3H-PIB and
3H-nicotine binding in different
brain regions of the autopsy tissue (P50.02, Fig. 8C). This ﬁnding
reﬂects that high ﬁbrillar load is accompanied by a loss of a4b2
neuronal nicotinic acetylcholine receptors in autopsy brain. No sig-
niﬁcant correlations were observed between in vivo
11C-PIB re-
tention or
3H-PIB binding versus
125I-a-bungarotoxin binding
(a7-neuronal nicotinic acetylcholine receptors).
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Figure 4 The values of the regional cerebral glucose metabol-
ism (rCMRglc) as measured by
18F-FDG in the left medial tem-
poral, left posterior cingulate and left lower parietal signiﬁcantly
correlated (P50.05) with attention, episodic memory and
Full-Scale Intelligence Quotient tests, respectively, during the
time of disease progression (from age 53 to 58 years).
Correlation was performed by using the stepwise regression
analysis.
308 | Brain 2011: 134; 301–317 A. Kadir et al.Additionally, no correlation was observed between regional
cerebral glucose metabolism and
3H-nicotine or
125I-a-
bungarotoxin binding, respectively (data not shown).
11C-Pittsburgh Compound B positron
emission tomography retention and
markers of inﬂammatory processes
at autopsy
A signiﬁcant positive correlation was observed between regional
in vivo
11C-PIB PET retention and the total number of glial ﬁbril-
lary acidic protein immunoreactive cells semiquantitatively assessed
in the autopsy brain (P50.03, Fig. 9A). Signiﬁcant positive correl-
ations were also found between
3H-PIB binding, extracellular Ab
plaques and the number of glial ﬁbrillary acidic protein immuno-
reactive cells (P50.01, Fig. 9B, Table 1).
No signiﬁcant correlation was observed between
11C-PIB reten-
tion or
3H-PIB binding and binding of
3H-PK11195 (activated
microglia) and
3H-L-deprenyl (activated astrocytes) in the autopsy
brain (data not shown).
A positive correlation was observed between regional
3H-L-deprenyl and
3H-PK11195 binding (P50.03, Fig. 9C) as
well as between
3H-L-deprenyl binding and butyrylcholinesterase
activity (P50.02, Fig. 9D). The highest butyrylcholinesterase ac-
tivity, as well as the highest binding of
3H-L-deprenyl and
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Figure 5 (A)
11C-PIB PET scans at 56 and 58 years of age. The
11C-PIB images were derived from dynamic summations of standard
uptake values (SUVs) over 40–60min and were normalized with the cerebellum as a reference region (SUV/Ref). The colour scale indicates
red (high), yellow (medium) and blue (low)
11C-PIB retention. The coregistered images represent transaxial, coronal and sagittal sections.
(B) Comparison of
11C-PIB retention data in two scans in the following brain regions: frontal cortex (FC) (composite of frontal, cingulate
anterior and frontal association cortices), parietal cortex (PC) (composite of upper and lower parietal cortices), parietotemporal cortex
(PTC), cingulate posterior (CP), occipital cortex (OC), temporal cortex (TC) (composite of temporal inferior and lateral), medial temporal
(MT), striatum (St), thalamus (Thal) and pons. With the exception of the pons, all brain regions are the average of the right and left
hemisphere. To enable comparison between scans 1 and 2, the standard uptake values were normalized, with the cerebellum as a
reference region. MMSE = mini-mental state examination.
PET imaging and molecular pathology in AD Brain 2011: 134; 301–317 | 3093H-PK11195, was observed in the anterior hippocampus in the
autopsy brain.
The regional cerebral glucose metabolism did not correlate with
either binding of
3H-PK11195,
3H-L-deprenyl or butyrylcholines-
terase activity measured at autopsy (data not shown).
None of the neuronal nicotinic acetylcholine receptors subtypes
correlated with any of the inﬂammatory markers studied (data not
shown).
Discussion
The signiﬁcant progress in the ﬁeld of molecular medicine has
advanced our knowledge of the sequence of neurodegenerative
events in the brain that lead to dementia disorders such as
Alzheimer’s disease. The development of different diagnostic bio-
markers measuring brain Ab and regional cerebral glucose
Figure 6 Immunoreactivity in Ab plaques: (A)A b1–42, (B)A b1–40, (C) 4G8, (D) 6E10 and (E) 6F/3D in the frontal cortex. 4G8
immunoreactivity was observed both in extracellular Ab plaques and in intracellular Ab deposits (C, bottom right insert). (F) Glial ﬁbrillary
acidic protein (GFAP) immunoreactivity in the frontal cortex. Note the round shapes strongly stained for GFAP (reactive astrocytes), as
presented in detail and by a white arrow (F, bottom right insert). (G, H) AT8 immunoreactivity for tau. A stronger immunoreactivity was
detected in the anterior hippocampus (Hippo A) than in the posterior hippocampus (Hippo P) (bottom right insert).
310 | Brain 2011: 134; 301–317 A. Kadir et al.metabolism by PET, and brain atrophy by MRI as well as CSF
biomarkers facilitates the early detection of Alzheimer’s disease
(Blennow et al., 2010; Frisoni et al., 2010; Nordberg et al.,
2010). The clinical beneﬁts of CSF biomarkers and
11C-PIB PET
imaging for early diagnosis of prodromal stages of Alzheimer’s
disease were recently recommended in the National Institute
on Ageing-Alzheimer Association draft diagnostic criteria guide-
lines (http://www.alz.org/reaearch/diagnostic_criteria). While
biomarker studies may provide insight into the dynamic relation-
ships between Alzheimer’s disease pathology, neurodegeneration
and cognition, autopsy studies are important for a secure founda-
tion on which to base further understanding of the cellular and
molecular changes that contribute to Alzheimer’s disease (Esiri,
2010; Jellinger, 2010).
The patient with Alzheimer’s disease described in this study vol-
unteered for the ﬁrst
11C-PIB PET scan in the world, in February
2002. The patient was clinically followed at regular intervals until
her death. Post-mortem neuropathological examination performed
35 months after the last
11C-PIB-PET scan conﬁrmed the clinical
diagnosis of Alzheimer’s disease with a pure Alzheimer’s disease
pathology at autopsy. The patient showed a continuous deterior-
ation in cognitive performance, which paralleled the decline in
regional cerebral glucose metabolism as observed at three-
repeated
18F-FDG scans. Meanwhile,
11C-PIB retention remained
stable between baseline and the 2 year follow-up, which is in
agreement with reports from other follow-up studies with
11C-PIB in patients with Alzheimer’s disease after one year (Jack
et al., 2009; Scheinin et al., 2009), 2 years (Engler et al., 2006)
and a 5 year follow-up (Kadir et al., 2010). In this study, we did
not observe any regional correlation between
11C-PIB retention
and regional cerebral glucose metabolism. However, previous stu-
dies have reported an inverse relation between
11C-PIB retention
and regional cerebral glucose metabolism, especially in the parietal
cortex (Klunk et al., 2004; Engler et al., 2006; Edison et al., 2007).
A high ﬁbrillar Ab plaque as measured by
11C-PIB was present in
this patient with Alzheimer’s disease, most notably in cortical re-
gions. We demonstrated that
11C-PIB retention measured by PET
at 56 and 58 years of age signiﬁcantly correlated with
region-matched autopsy quantiﬁcation of Ab, measured by both
3H-PIB binding and enzyme-linked immunosorbent assay detection
of total levels of insoluble Ab (Ab40 and Ab42). Two other studies
have reported correlations between in vivo
11C-PIB retention and
Ab deposited in autopsy brains (Bacskai et al., 2007; Ikonomovic
et al., 2008). Bacskai et al. (2007) studied a case of dementia with
Lewy bodies and extensive cerebral Ab angiopathy, where the
11C-PIB PET imaging had been performed 3 months prior to
death. Ikonomovic et al. (2008) investigated a patient with
Alzheimer’s disease with typical clinical symptoms who underwent
in vivo
11C-PIB-PET imaging, and brain autopsy performed 10
months later. In addition, patients with high ﬁbrillar Ab levels in
frontal cortical biopsy specimens have shown high
11C-PIB reten-
tion in the brain 3 years later (Leinonen et al., 2008). Altogether,
these studies conﬁrm that
11C-PIB retention in the brain is asso-
ciated with levels of insoluble, but not soluble Ab. Similar results
have been obtained in in vitro studies with PIB binding to syn-
thetic Ab ﬁbrils and insoluble Ab deposits in human post-mortem
brain tissues (Klunk et al., 2005; Bacskai et al., 2007; Lockhart
et al., 2007; Ikonomovic et al., 2008; Cairns et al., 2009;
Svedberg et al., 2009).
Subsequently, we examined in detail the regional distribution of
Ab plaques in the autopsy brain with immunohistochemistry using
ﬁve antibodies with different speciﬁcity for amino acid residues
reactive to the human Ab peptide. The distribution revealed
large extracellular deposits of Ab plaques in cortical areas that
correlated signiﬁcantly with both
11C-PIB retention measured by
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Figure 7 In vivo
11C-PIB PET standard uptake values (SUVs) in
nine different brain regions of the patient with Alzheimer’s dis-
ease signiﬁcantly and positively correlated with (A)
3H-PIB
binding (fmol/mg tissue) and with (B) total insoluble Ab levels
(fmol/mg tissue) measured in autopsy tissue in the correspond-
ing brain regions. In the correlation analysis the following nine
brain areas were used: frontal cortex (FC), temporal cortex (TC),
parietal cortex (PC), occipital cortex (OC), anterior hippocampus
(Hip A), posterior hippocampus (Hip P), striatum (St), thalamus
(Thal) and cerebellum (Cb), Left (lt) hemisphere. Note that for
the in vivo and autopsy correlation analysis, the last
11C-PIB PET
scan used was 35 months prior to death.
PET imaging and molecular pathology in AD Brain 2011: 134; 301–317 | 311PET and
3H-PIB binding. Similar labelling of Ab deposits being
detected in sections from human Alzheimer’s disease neocortex
have been reported in other studies, where investigators used
some of the same antibodies applied in this study (Klunk et al.,
2004; Lockhart et al., 2007; Ikonomovic et al., 2008).
By using the 4G8 antibody, we found higher intracellular Ab
deposition in the hippocampus than in other brain areas. This
observation suggests that there may be differences in the brain
regions regarding the internal and external localization of Ab,a sa
consequence of the disease state or tissue characteristics.
Alternatively, we suggest that these differences observed in 4G8
immunoreactivity could be related to the vulnerability of speciﬁc
populations of cells in some regions of the brain and to the
dynamic relationship between the pools of intracellular and
extracellular Ab. It has been suggested that intracellular accumu-
lation of Ab interfering with the synaptic activity, occurs prior to
extracellular accumulation forming the Ab plaques (Tampellini and
Gouras, 2010). The
11C-PIB retention did not correlate with intra-
cellular Ab. This probably reﬂects that PIB binds preferentially to
extracellular ﬁbrillar Ab and less to intracellular Ab; however future
studies investigating this issue as well PIB binding to other forms
of Ab, such as various Ab oligomers, are warranted.
The hippocampus is a region that typically shows dense neuro-
ﬁbrillary tangle distribution (Thangavel et al., 2009), which was
evident in this study by the widespread and characteristic distribu-
tion pattern of neuroﬁbrillary tangles in this speciﬁc region in the
autopsy tissue. The reduction of regional cerebral glucose metab-
olism in susceptible brain regions measured in vivo by
18F-FDG
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Figure 8 (A) Vertical bars (mean  SD) showing
3H-nicotine binding (fmol/mg protein) in different brain regions in an age-matched
control group [historical data collected from our research laboratory; n = 7, mean age: 70  3.1 (SD)]. Open circles within the vertical bars
indicates the
3H-nicotine binding (fmol/mg protein) in the same brain regions of the patient with Alzheimer’s disease. (B) In vivo
11C-PIB
PET standard uptake values (SUV) and (C) in vitro
3H-PIB binding (fmol/mg tissue) in the patient with Alzheimer’s disease correlated
negatively with
3H-nicotine binding (fmol/mg tissue). Nine brain areas in left (lt) hemisphere were analysed for the correlations: frontal
cortex (FC), temporal cortex (TC), parietal cortex (PC), occipital cortex (OC), anterior hippocampus (Hip A), posterior hippocampus
(Hip P), striatum (St), thalamus (Thal) and cerebellum (Cb).
312 | Brain 2011: 134; 301–317 A. Kadir et al.PET paralleled the ﬁnding of an increased number of neuroﬁbril-
lary tangles in the hippocampus, probably as a marker of neuro-
degeneration, synaptic activity and clinical progression of
Alzheimer’s disease (Ingelsson et al., 2004; Engler et al., 2006;
von Gunten et al., 2006; Kadir et al., 2010). We found no
correlation between
11C-PIB retention and the number of
neuroﬁbrillary tangles in either the cerebral cortex or the hippo-
campus, conﬁrming the earlier observation by Ikonomovic et al.
(2008), who also demonstrated the possibility of PIB binding
in vitro to a subset of extracellular (ghost) tangles in the entorh-
inal cortex.
Congo red staining in autopsy brain of this patient with
Alzheimer’s disease showed several positive vessels in the lepto-
meninges and the cortex consistent with cerebral amyloid angio-
pathy, which is commonly observed in patients with Alzheimer’s
disease. In a series of autopsy cases, covering 117 subjects with
clinical Alzheimer’s disease, 80% had demonstrable Ab deposits
within blood vessels, (Ellis et al., 1996). The presence of cerebral
amyloid angiopathy was higher in patients with Alzheimer’s dis-
ease having at least one ApoE e4 allele (Pfeifer et al., 2002). It has
been shown that
3H-PIB binds to both ﬁbrillar and vascular Ab
(Bacskai et al., 2007; Lockhart et al., 2007; Ikonomovic et al.,
2008). In subjects with cerebral amyloid angiopathy, vascular Ab
could be a major contributor to the in vivo
11C-PIB signal
(Johnson et al., 2007; Ly et al., 2010). However, cerebral amyloid
angiopathy pathology has an occipital predilection, resulting in a
greater occipital
11C-PIB retention compared to patients with
Alzheimer’s disease (Johnson et al., 2007; Ly et al., 2010).
Although we found that Ab was present in the blood vessels in
the autopsy Alzheimer’s disease brain, we consider that
11C-PIB
binding to cerebral amyloid angiopathy contributed very little to
the total in vivo
11C-PIB retention.
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Figure 9 (A) Regional brain
11C-PIB retention as measured by PET values, (B)
3H-PIB binding (fmol/mg tissue) in the autopsy tissue of the
patient with Alzheimer’s disease correlated positively with the total number of glia cells as measured by glial ﬁbrillary acidic protein (GFAP)
immunoreactivity. (C) Positive correlations were found between
3H-L-deprenyl and
3H-PK11195 binding, as measured in different brain
regions in the patient with Alzheimer’s disease. (D) Regional
3H-L-deprenyl binding correlated positively with butyrylcholinesterase
activity. Nine brain areas were analysed: frontal cortex (FC), temporal cortex (TC), parietal cortex (PC), occipital cortex (OC), anterior
hippocampus (Hip A), posterior hippocampus (Hip P), striatum (St), thalamus (Thal) and cerebellum (Cb). SUV = standard uptake value,
rt = right, lt = left.
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well established in Alzheimer’s disease. We have earlier demon-
strated signiﬁcant losses of neuronal nicotinic acetylcholine recep-
tors, especially a4b2 neuronal nicotinic acetylcholine receptors, in
autopsy studies of Alzheimer’s disease brain tissue as well as by
11C-nicotine PET (Paterson and Nordberg, 2000). Moreover, we
have veriﬁed with
11C-nicotine PET that the cortical decline in
11C-nicotine binding observed in vivo correlates with the cognitive
impairment of the patients with Alzheimer’s disease (Kadir et al.,
2006). Reports from several experimental studies also suggest a
link between brain neuronal nicotinic acetylcholine receptors and
Ab accumulation in Alzheimer’s disease (D’Andrea et al., 2001;
Dineley et al., 2002; Nagele et al., 2002; Dougherty et al.,
2003; Clifford et al., 2008). In the present study, we quantiﬁed
two of the major neuronal nicotinic acetylcholine receptor sub-
types (a4b2 and a7 neuronal nicotinic acetylcholine receptors) in
different brain regions of the autopsy tissue in the patient with
Alzheimer’s disease. Low
3H-nicotine binding was measured in
brain regions with high
11C-PIB retention, and a strong correlation
was found between
3H-PIB and
3H-nicotine binding at autopsy. In
an unrelated PET study, including a cohort of seven patients with
mild Alzheimer’s disease, we observed a signiﬁcant negative cor-
relation between
11C-PIB retention and
11C-nicotine binding (un-
published observations), which supports our current ﬁndings in
autopsy brain tissue. The stronger correlation between
3H-nicotine and
3H-PIB at autopsy compared with
11C-PIB
in vivo may be due to the gradual loss of neuronal nicotinic
acetylcholine receptors occurring during Alzheimer’s disease pro-
gression (neurodegeneration) in comparison to the relatively stable
Ab levels measured by
11C-PIB PET (Nordberg et al. 2010). An
alternative explanation is that there might be a slight difference in
Ab measured by
11C-PIB compared with
3H-PIB. It is possible that
studies with
3H-nicotine binding at autopsy might more readily
detect this difference. This new observation regarding a4b2 neur-
onal nicotinic acetylcholine receptors and ﬁbrillar Ab is of great
interest, and further studies are required to validate this ﬁnding
and to elucidate the role of neuronal nicotinic acetylcholine recep-
tors in amyloid pathology.
Experimental studies have previously demonstrated that soluble
forms of Ab bind to a7 neuronal nicotinic acetylcholine receptors
(Liu et al., 2001; Lee and Wang, 2003; Lilja et al., 2010). It has
previously been shown that the a7 neuronal nicotinic acetylcholine
receptors are present both on neurons as well as on glia cells, and
these receptors have been reported to be reduced on neurons in
autopsy brain tissue from patients with Alzheimer’s disease (Yu
et al., 2005) and increased on astrocytes (Teaktong et al., 2003;
Yu et al., 2005). Although an increased number of a7 neuronal
nicotinic acetylcholine receptors in autopsy brain tissue from pa-
tients with Alzheimer’s disease with high Ab load in brain was
recently reported (Ikonomovic et al., 2009), we did not observe
any correlation between either regional
11C-PIB retention in vivo
or
3H-PIB and a7 neuronal nicotinic acetylcholine receptors as
measured by
125I-a-bungarotoxin binding in the present study. It
may be difﬁcult in tissue homogenates to distinguish between a7
neuronal nicotinic acetylcholine receptors localized on neurons
versus astrocytes, which could be a possible explanation as to
why we did not observe any correlation with ﬁbrillar Ab levels.
The consequence and the time course of inﬂammatory pro-
cesses, in relation to ﬁbrillar Ab during the progression of
Alzheimer’s disease, are still under investigation. Increased num-
bers of both activated microglial cells and reactive astrocytes are
often observed in the vicinity of the ﬁbrillar core of Ab plaques in
the Alzheimer’s disease autopsy brain (Braak et al., 1998; Zhu
et al., 1999). These observations suggest that the increase in acti-
vated microglia and activated astrocytes may reﬂect attempts by
these glial cells to clear Ab in the brain. However, when the dis-
ease progresses, they may instead potentiate neurotoxicity by
releasing toxic immune mediators (McGeer et al., 2000).
Increased binding of
3H-PK-11195, a peripheral-type benzodi-
azepine binding site ligand, has been measured in homogenates
from Alzheimer’s disease brains reﬂecting an increase in microglia/
macrophages (Diorio et al., 1991; Saura et al., 1994). Similarly,
increased monoamine oxidase B activity has been measured in Ab
plaque-associated astrocytes with other monoamine oxidase B lig-
ands such as
3H-lazabemide (Saura et al., 1994) and
3H
L-deprenyl (Jossan et al., 1991b). Both
11C-PK11195 and
11C-L-deuterodeprenyl have been used as PET ligands for visualiz-
ing activated microglia and astrocytes, respectively (Cagnin et al.,
2001; Engler et al., 2003) in neurodegenerative diseases. While a
strong binding signal of these tracers is detected in multiple scler-
osis (Debruyne et al., 2003) and Creutzfeldt-Jacob disease (Engler
et al., 2003), the
11C-PK11195 binding has varied in Alzheimer’s
disease in different PET studies. Increased binding of
11C-PK11195
was reported in cortical regions of patients with mild Alzheimer’s
disease when compared with healthy controls (Cagnin et al.,
2001). In more recent PET studies, low
11C-PK1195 binding was
measured in patients with Alzheimer’s disease and mild cognitive
impairment (Okello et al., 2009; Wiley et al., 2009). Increased
11C-PK1195 binding was observed by Edison et al. (2008) in re-
gions associated with high
11C-PIB retention, further demonstrat-
ing an inverse correlation between cognition and levels of cortical
11C-PK1195 binding measured by PET. In a recent PET study in
patients with mild cognitive impairment, the investigators did not
ﬁnd such a correlation between
11C-PK11195 and
11C-PIB reten-
tion (Okello et al., 2009). Similarly, we did not observe any rela-
tion between
11C-PIB retention or
3H-PIB and
3H-PK1195 binding
in the present study. A possible explanation for these different
ﬁndings with
11C-PK11195 might be changes in binding afﬁnity
during different stages of microglia activation (Vas et al., 2008).
In the current study, a positive correlation was found between
glial ﬁbrillary acidic protein immunopositive cells and in vivo
11C-PIB retention as well as
3H-PIB binding and extracellular Ab
quantiﬁed by immunohistochemistry. This ﬁnding supports the as-
sumption that astrocytosis is located in close proximity to ﬁbrillar
Ab plaque formation (Simpson et al., 2010). A positive correlation
has been demonstrated between
3H-lazabemide (monoamine oxi-
dase B inhibitor) and glial ﬁbrillary acidic protein immunoreactivity
in the Alzheimer’s disease brain (Saura et al., 1994). We found no
relationship between regional
11C-PIB retention or
3H-PIB binding
and
3H-L-deprenyl binding in the autopsy brain. The lack of a
correlation between
3H-L-deprenyl binding and ﬁbrillar Ab might
reﬂect low binding of
3H-L-deprenyl to monoamine oxidase B in
autopsy brain tissue. This does not exclude the use of
11C-L-deuterodeprenyl as an in vivo PET tracer for detecting
314 | Brain 2011: 134; 301–317 A. Kadir et al.early changes in activated astrocytes. In support, we have recently
observed an increase in
11C-L-deuterodeprenyl binding in patients
with mild cognitive impairment and mild Alzheimer’s disease com-
pared to controls (Carter et al., 2010). No correlation was
observed between regional changes in
11C-L-deuterodeprenyl
binding and
11C-PIB retention or regional cerebral glucose metab-
olism, respectively (Carter et al., 2010).
In the present study, we found a positive correlation between
regional
3H-L-deprenyl and butyrylcholinesterase activity, probably
reﬂecting a pathophysiological consequence of butyrylcholinester-
ase activity on inﬂammatory processes in the Alzheimer’s disease
brain (Darreh-Shori et al., 2009). An increased brain butyrylcholi-
nesterase activity has been attributed to an increase in the preva-
lence of reactive glial cells and Ab plaques, to which this enzyme is
localized (Perry et al., 1978; Geula and Mesulam, 1995; Lehmann
et al., 2000; Tasker et al., 2005). We have recently observed a
strong positive correlation between CSF butyrylcholinesterase ac-
tivity and cortical
11C-PIB retention (Darreh-Shori et al., 2010).
Interestingly,
3H-L-deprenyl,
3H-PK11195 and butyrylcholinester-
ase all showed high binding and activity in the hippocampus, a
region characterized by a high amount of neuroﬁbrillary tangles as
a sign for neurodegenerative processes.
In conclusion, this study conﬁrmed the pure Alzheimer’s disease
pathology of the ﬁrst
11C-PIB PET imaged patient with Alzheimer’s
disease. We demonstrated a strong correlation between ﬁbrillar Ab
measured by PET and at autopsy several years later. Loss of neur-
onal nicotinic acetylcholine receptors (a4b2 subtype) at autopsy
was associated with high levels of ﬁbrillar Ab, suggesting that
neuronal nicotinic acetylcholine receptors, as markers for degen-
erative processes, may closely be linked to Ab pathology.
Although, we found a positive correlation between glial ﬁbrillary
acidic protein immunoreactivity and ﬁbrillar Ab, measured by PET
as well as at autopsy, the lack of a correlation between ﬁbrillar Ab
and binding of the two PET tracers PK11195 and deprenyl in
autopsy tissue, suggests that these tracers should further be stu-
died in vivo by PET in order to gain a better understanding of the
time course for early changes in neuroinﬂammatory processes in
relation to Ab in Alzheimer’s disease.
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